Milestone marks transition of Inimmune Corporation to a clinical-stage company.
New Diagnostic Tests Could Change Leukemia Prevention and Treatment
A Montana based molecular diagnostic company, Alercell Inc., is pioneering novel techniques to augment the way leukemia is diagnosed, treated and ultimately prevented.
Solo-Dex, Inc. Strikes Groundbreaking Agreement for Distribution in Saudi Arabia of its Fascile(R) Non-Opioid Acute Pain Management Suite
Wolf Creek company Solo-Dex, a leading player in the development, manufacture, and sales of innovative non-opioid acute pain management solutions, is pleased to announce a strategic master distribution agreement with CH Trading Group LLC and Farouk, Maamoun Tamer & Co. This groundbreaking partnership will pave the way for the distribution of Solo-Dex’s revolutionary Fascile® suite of products within the Kingdom of Saudi Arabia.
“Fighting like a mother” — UM Neuroscience Hunts Cure for Young Boy
Amber Freed was like any mother looking for answers. Her twins – born in 2017 – were still babies when she and her husband noticed Maxwell wasn’t advancing at the same pace as his sister, Riley. The doctors tried to reassure the family, but Freed knew there was something wrong. Soon the doctors did, too.
Alercell celebrates National Cancer Survivors’ Day® 2023
The National Cancer Survivors’ Day Foundation invites all cancer survivors to celebrate on June 4 and Alercell joins all survivors to celebrate another beautiful day of life. The date marks the 36th annual Celebration of Life.
Tonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the University of Washington to Study TNX-1900 (Potentiated Intranasal Oxytocin) for Social Anxiety Disorder
Social Anxiety Disorder Affects 15 Million U.S. Adults and is More Common Among Women than Men
FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval
The U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit.
NIH Grants and Funding Opportunities Announced
The PHS 2023-2 omnibus solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications have been released. The first application due date is Tuesday, September 5, 2023.
Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLC
Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray) are indicated for the treatment of acute migraine in adults. Strategic acquisition helps build Tonix’s commercial capabilities and infrastructure ahead of potential launch of TNX-102 SL for the treatment of fibromyalgia.